Cargando…

Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial

Significant hepatocellular carcinoma (HCC) risk persists after chronic hepatitis C (CHC) cure. Preclinical studies have shown that erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, has an antiviral activity and HCC chemopreventive effect. Erlotinib is metabolized in the liver, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saviano, Antonio, Habersetzer, François, Lupberger, Joachim, Simo-Noumbissie, Pauline, Schuster, Catherine, Doffoël, Michel, Schmidt-Mutter, Catherine, Baumert, Thomas F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236598/ https://www.ncbi.nlm.nih.gov/pubmed/35363627 http://dx.doi.org/10.14309/ctg.0000000000000492

Ejemplares similares

Boceprevir and personalized medicine in hepatitis C virus infection
por: Habersetzer, François, et al.
Publicado: (2012)

CD81-Receptor Associations — Impact for Hepatitis C Virus Entry and Antiviral Therapies
por: Zona, Laetitia, et al.
Publicado: (2014)

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents
por: Xiao, Fei, et al.
Publicado: (2014)

Genotype 1 Hepatitis C Virus Envelope Features That Determine Antiviral Response Assessed through Optimal Covariance Networks
por: Murray, John M., et al.
Publicado: (2013)

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
por: Xiao, Fei, et al.
Publicado: (2015)

Tight Junction Proteins and the Biology of Hepatobiliary Disease
por: Roehlen, Natascha, et al.
Publicado: (2020)

Targeting the Host for New Therapeutic Perspectives in Hepatitis D
por: Turon-Lagot, Vincent, et al.
Publicado: (2020)

Safe administration of corticosteroids in severe ulcerative colitis and active SARS-CoV2 infection
por: Mayer, Pierre, et al.
Publicado: (2020)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Signaling Induced by Chronic Viral Hepatitis: Dependence and Consequences
por: Boulahtouf, Zakaria, et al.
Publicado: (2022)

PI4K-beta and MKNK1 are regulators of hepatitis C virus IRES-dependent translation
por: Lupberger, Joachim, et al.
Publicado: (2015)

Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges
por: Lupberger, Joachim, et al.
Publicado: (2021)

Memories of Stress: The Imprinted Cancer Risk After HCV Cure
por: Lupberger, Joachim, et al.
Publicado: (2023)

Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development
por: Virzì, Alessia, et al.
Publicado: (2021)

HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response
por: Hamdane, Nourdine, et al.
Publicado: (2019)

Adaptive Immunity to Hepatitis C Virus
por: Zeisel, Mirjam B., et al.
Publicado: (2009)

Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip
por: Goto, Kaku, et al.
Publicado: (2020)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

Interferon revisited: Peering behind the lines of antiviral defense
por: Virzì, Alessia, et al.
Publicado: (2020)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
por: Sueangoen, Natthaporn, et al.
Publicado: (2020)

Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection
por: Zeisel, Mirjam B., et al.
Publicado: (2015)

The major form of hepatitis C virus alternate reading frame protein is suppressed by core protein expression
por: Wolf, Marie, et al.
Publicado: (2008)

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
por: Park, Jin H., et al.
Publicado: (2012)

Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months
por: Gonçalves, Ivone, et al.
Publicado: (2013)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
por: Tan, Lavinia, et al.
Publicado: (2023)

Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes
por: Verrier, Eloi R., et al.
Publicado: (2016)

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
por: Wakelee, Heather A., et al.
Publicado: (2017)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
por: Bartholomeusz, Chandra, et al.
Publicado: (2011)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Excellent response to erlotinib in breast carcinoma with rare EGFR mutation—a case report
por: Singh, Gunjesh Kumar, et al.
Publicado: (2020)

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky
por: Larson, Kara L., et al.
Publicado: (2020)

Host-targeting therapies for hepatitis C virus infection: current developments and future applications
por: Crouchet, Emilie, et al.
Publicado: (2018)

Oncogenic Signaling Induced by HCV Infection
por: Virzì, Alessia, et al.
Publicado: (2018)

Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease
por: Roca Suarez, Armando Andres, et al.
Publicado: (2021)

Hepatitis B virus compartmentalization and single-cell differentiation in hepatocellular carcinoma
por: Jühling, Frank, et al.
Publicado: (2021)

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
por: Baumert, Thomas F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jjvvs7vlspg3obt9ddsl5aho7e